Charles River Laboratories International, Inc.
CRL
$155.46
$2.801.83%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.83% | -0.49% | 0.59% | -2.71% | -1.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.83% | -0.49% | 0.59% | -2.71% | -1.08% |
| Cost of Revenue | -2.56% | 1.67% | -1.49% | -2.23% | 3.59% |
| Gross Profit | 2.87% | -4.25% | 4.30% | -3.59% | -9.76% |
| SG&A Expenses | -0.63% | -7.30% | 12.04% | -0.51% | -0.56% |
| Depreciation & Amortization | 123.21% | -15.43% | -10.73% | 16.84% | 21.17% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.50% | -0.92% | 0.83% | -1.32% | 3.35% |
| Operating Income | -47.39% | 2.05% | -0.62% | -10.70% | -32.31% |
| Income Before Tax | -35.66% | -4.43% | -40.31% | -63.66% | -203.87% |
| Income Tax Expenses | -485.05% | 51.07% | -26.26% | -58.82% | -115.41% |
| Earnings from Continuing Operations | -29.26% | -20.97% | -44.10% | -65.26% | -213.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 64.57% | -77.74% | -103.89% | 73.13% | 59.96% |
| Net Income | -28.93% | -21.87% | -44.38% | -65.09% | -214.65% |
| EBIT | -47.39% | 2.05% | -0.62% | -10.70% | -32.31% |
| EBITDA | 12.90% | -30.05% | 26.18% | -7.03% | -27.22% |
| EPS Basic | -33.22% | -17.25% | -39.01% | -61.60% | -215.69% |
| Normalized Basic EPS | -10.95% | -11.29% | 6.31% | -20.38% | -60.99% |
| EPS Diluted | -33.22% | -17.29% | -39.08% | -61.53% | -216.41% |
| Normalized Diluted EPS | -10.95% | -11.35% | 6.56% | -20.13% | -60.75% |
| Average Basic Shares Outstanding | -3.76% | -4.24% | -4.66% | -1.48% | -0.34% |
| Average Diluted Shares Outstanding | -3.76% | -4.18% | -4.88% | -1.78% | -0.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |